ReviewNeuropsychiatric disease and treatment2014
Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.
Review in Neuropsychiatric disease and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Pilot randomized controlled trial of a hospital-based substance use treatment and recovery team (START) to improve initiation of medication for alcohol or opioid use disorder and linkage to follow-up care.Journal of substance use and addiction treatment · 2023Trial
- Initiation and engagement as mechanisms for change caused by collaborative care in opioid and alcohol use disorders.Drug and alcohol dependence · 2018Trial
- Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Patient predictors of substance use disorder treatment initiation in primary care.Journal of substance abuse treatment · 2018Trial
- An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol.Implementation science : IS · 2015Trial
- Article
- Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.BMC psychiatry · 2022Article
- Virtual opioid agonist treatment: Alberta's virtual opioid dependency program and outcomes.Addiction science & clinical practice · 2022Article
- Prospective Prediction of Lapses in Opioid Use Disorder: Protocol for a Personal Sensing Study.JMIR research protocols · 2021Article
- Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018.Preventive medicine · 2020Article
- Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men.Addiction & health · 2018Article
- Buprenorphine/Naloxone (ZubsolvCNS drugs · 2018Review
- Sustaining alcohol and opioid use disorder treatment in primary care: a mixed methods study.Implementation science : IS · 2018Article
- Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.BMC family practice · 2017Article
- Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study.The International journal on drug policy · 2017Article
- Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population.Medical care · 2017Article
- Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults.Addictive behaviors · 2016Article
- Hypothesizing that a Pro-Dopaminergic Regulator (KB220zClinical medical reviews and case reports · 2016Article
- Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals.Substance abuse and rehabilitation · 2016Review
- Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors.Science signaling · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo review current evidence on buprenorphine-naloxone (bup/nx) for the treatment of opioid-use disorders, with a focus on strategies for clinical management and office-based patient care. QUALITY OF EVIDENCE: Medline and the Cochrane Database of Systematic Reviews were searched. Consensus reports, guidelines published, and other authoritative sources were also included in this review. Apart from expert guidelines, data included in this review constitute level 1 evidence.
findingsBup/nx is a partial μ-opioid agonist combined with the opioid antagonist naloxone in a 4:1 ratio. It has a lower abuse potential, carries less stigma, and allows for more flexibility than methadone. Bup/nx is indicated for both inpatient and ambulatory medically assisted withdrawal (acute detoxification) and long-term substitution treatment (maintenance) of patients who have a mild-to-moderate physical dependence. A stepwise long-term substitution treatment with regular monitoring and follow-up assessment is usually preferred, as it has better outcomes in reducing illicit opioid use, minimizing concomitant risks such as human immunodeficiency virus and hepatitis C transmission, retaining patients in treatment and improving global functioning.
conclusionBup/nx is safe and effective for opioid detoxification and substitution treatment. Its unique pharmaceutical properties make it particularly suitable for office-based maintenance treatment of opioid-use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.